Bovine viral diarrhoea virus inactivated vaccine and preparation method thereof

A technology for bovine viral diarrhea and inactivated vaccine, which is applied in the field of veterinary biological products and can solve problems such as economic losses

Active Publication Date: 2018-03-23
QILU ANIMAL HEALTH PROD
View PDF6 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, BVDV is also a potential source of contamination of bovine biological products (serum, frozen semen, etc.), causing huge economic losses to related fields

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bovine viral diarrhoea virus inactivated vaccine and preparation method thereof
  • Bovine viral diarrhoea virus inactivated vaccine and preparation method thereof
  • Bovine viral diarrhoea virus inactivated vaccine and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0063] ——Preparation of inactivated vaccine against bovine viral diarrhea

[0064] 1. Antigen Preparation

[0065] This embodiment provides the preparation of BVDV-L strain, BVDV-L2 strain, BVDV-T strain, and BVDV-D strain virus by using spinner bottle adherent culture, suspension culture technology, and microcarrier suspension culture technology to cultivate bovine kidney cell line (MDBK) Methods.

[0066] (1) Prepare BVDV-L strain, BVDV-L2 strain, BVDV-T strain, BVDV-D strain antigen by using spinner bottle adherent culture cells

[0067] 1) Cultivate cells: First, resuscitate the bovine kidney cell line MDBK into a cell flask, grow for about 48 hours, digest with EDTA-trypsin cell dispersion, and passage according to the volume ratio of 1:3. Add cell growth medium (DMEM medium containing 10% (v / v) calf serum, pH value 7.0) for spinner bottle culture, when the cells cover 90% to 100% of the monolayer, it is used to inoculate BVDV-L respectively strain, BVDV-L2 strain, BVD...

Embodiment 2

[0093] ——Inspection of finished products of bovine viral diarrhea inactivated vaccine

[0094] 1. Sterility test: according to the appendix of the current "Chinese Veterinary Pharmacopoeia", it should meet the requirements. The above test results are shown in Table 2.

[0095] Table 2 Physical properties, sterility test results

[0096]

[0097] 2. Safety inspection

[0098] (1) Alternative to animal testing

[0099] 1) Monovalent vaccine (BVDV I a inactivated vaccine, BVDV I b inactivated vaccine, BVDV II a inactivated vaccine and BVDV II b inactivated vaccine):

[0100] Each vaccine used 6 healthy rabbits of 1.5-2.0 kg, including 4 in the immunization group and 2 in the control group. The rabbits in the immunization group were injected with 1.0ml of vaccine in each leg muscle, and the rabbits in the control group were injected into each leg muscle. 1.0ml of cell culture was observed continuously for 7 days and body temperature was measured at fixed points every aftern...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an inactivated vaccine of a bovine viral diarrhoea virus (BVDV) and a preparation method of the inactivated vaccine, and belongs to the field of veterinary biological products. The vaccine is composed of four gene subtypes including BVDV I a, BVDV I b, BVDV II a and BVDV II b. The bovine viral diarrhoea inactivated vaccine is prepared by carrying out virus proliferation byusing a continuous cell line cultured by cell spinner bottles, full suspension and micro carriers, and optimizing a vaccine preparation process and the like. Safety and effectiveness testing resultsof the vaccine show that bovines are free of local and systemic adverse reactions after the bovine is immunized by the bovine viral diarrhoea virus inactivated vaccine; all the bovines receive immuneprotection; the vaccine is safe and reliable, and is capable of preventing diseases caused by different BVDV gene subtypes. The vaccine also comprises various types of monovalent inactivated vaccines,bivalent inactivated vaccines and tetravalent inactivated vaccines prepared from the four gene subtypes above.

Description

technical field [0001] The invention relates to an inactivated vaccine of bovine viral diarrhea virus and a preparation method thereof, belonging to the field of veterinary biological products. Background technique [0002] Bovine viral diarrhea (BVD) is a viral infectious disease caused by Bovine viral diarrhea virus (BVDV) belonging to Flaviviridae and Pestivirus genus, mainly affecting cattle, sheep, Deer, cattle, pigs and other animals, cattle of all ages are susceptible. The main clinical manifestations are diarrhea, acute and chronic mucosal diseases, persistent infection and immune tolerance, immunosuppression, abortion or deformed fetuses in pregnant dams. The disease was first discovered in the United States by Olafson et al. in 1946. It is characterized by fever, diarrhea and cough, and is called bovine viral diarrhea. Ramsey and Chiverst first discovered Mucosal disease (MD) in 1953, and the American Veterinary Medical Association named it Bovine Viral Diarrhea / ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/12A61K39/295A61K39/39A61P31/14C12N7/00C12N7/06
CPCA61K39/12A61K39/39A61K2039/5252A61K2039/552A61K2039/70C12N7/00C12N2770/24063C12N2770/24334
Inventor 徐龙涛毕玉彧高凤王蕾禚宝山
Owner QILU ANIMAL HEALTH PROD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products